Open an account

Crescent Biopharma

CBIO · NASDAQ

$13.07+$0.71 (+5.74%)TodayMarket closed ·
Prev close $12.36

About CBIO

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Employees
44
Headquarters
Waltham, Massachusetts
Listed
Jan 10, 2014
Sector
Health Care
Industry
Biotechnology
Website
crescentbiopharma.com

CBIO key statistics

Market cap
485.47M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
373.22K
Volume
299.62K
Open price
$12.40
High today
$13.63
Low today
$12.40
52 Week high
$27.41
52 Week low
$8.72

Crescent Biopharma (CBIO) at a glance

Crescent Biopharma (CBIO) last traded at $13.07, with a market cap of 485.47M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.40 and $13.63. The current price is 5.4% above the day's low and 4.1% below its high.

Volume so far is 299.62K shares, in line with the average of 373.22K shares a day.

Over the past year Crescent Biopharma has ranged from $8.72 to $27.41, and now sits 23% of the way up that range.

Crescent Biopharma met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.74 per share against an estimate of -$0.8109.

The average analyst price target is $31.21, 138.8% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $31.21
Low
$27.27
Now
$13.07
High
$36.75

CBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 30.1% on average.

  1. Q1 FY24: reported -$17.00 per share against an estimate of -$16.83
  2. Q2 FY24: reported -$16.00 per share against an estimate of -$17.08
  3. Q1 FY25: reported -$4.00 per share against an estimate of -$5.10
  4. Q2 FY25: reported -$4.93 per share against an estimate of -$1.80
  5. Q3 FY25: reported -$1.27 per share against an estimate of -$2.02
  6. Q4 FY25: reported -$0.54 per share against an estimate of -$2.57
  7. Q1 FY26: reported -$0.70 per share against an estimate of -$0.9655
  8. Q2 FY26: reported -$0.74 per share against an estimate of -$0.8109

CBIO news

  • Avi Kapoor

    Crude Oil Down 3%; Chevron Posts Mixed Q1 Results

  • Avi Kapoor

    Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Market-Moving News for December 4th

  • Press releaseGlobe Newswire

    Crescent Biopharma to Present at September Investor Conferences

  • Avi Kapoor

    Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as Crescent Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.